

Date: 30th May, 2025

To,
The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services
P.J Towers, Dalal Street,
Mumbai 400001

Script Code: 540359

Sub: Integrated Filing (Financial) for the quarter ended on 31st March, 2025.


Dear Sir/Madam,

In accordance with amendments to the SEBI (Listing Obligations and Disclosure requirements) (Third Amendment) Regulations, 2024 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated 31st December, 2024 read with BSE circular No. 20250102-4 dated 2nd January, 2025, the Integrated filing of financials for the quarter ended on 31st March, 2025 is enclosed herewith.

You are requested to kindly take the above information on your record.

Thanking you.

For **Parmax Pharma Limited**


Bhakti Aghera
Company Secretary

Statement of Standalone Audited Results for the Quarter & Financial year ended 31.03.2025						
(in Rs. Thousands)						
Sr. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
	(Refer Notes Below)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I.	Revenue from operations	48257.28	62844.41	42574.70	282039.58	110530.35
II.	Other income	-976.63	127.03	141.38	395.78	481.16
III.	Total Income (I+II)	47280.65	62971.44	42716.08	282435.36	111011.50
IV.	Expenses	0		0.00		
	(a) Cost of materials consumed	29611.25	49668.13	47650.89	215379.62	70292.73
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade		-4106.53			
		7482.43		-15010.35	-25.00	230.00
	(d) Employee benefits expense	5748.55	8437.84	4988.82	29883.40	29107.93
	(e) Finance Costs	2376.63	1064.05	1625.48	5855.39	6216.78
	(f) Depreciation and amortisation expense	-1769.57	4090.67	4068.95	10316.94	17116.70
	(g) Other expenses	11071.15	7762.45	12950.06	34256.42	44606.10
	Total expenses (IV)	54520.49	66916.61	56273.85	295666.77	167570.25
V	Profit/(Loss) from operations before exceptional items and tax (I-IV)	-7239.84	-3945.16	-13557.77	-13231.42	-56558.74
VI	Exceptional Items	10719.64	0.00	0.00	10719.64	0
VII	Profit/ (Loss) before tax (V-VI)	-17959.48	-3945.16	-13557.77	-23951.06	-56558.74
VIII	Tax expense:	0.00		0.00		
	(1) Current tax	0.00	0.00	0.00	0.00	0.00
	(2) Deferred tax	-3010.96	0.00	946.47	-3010.96	946.47
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	-14948.52	-3945.16	-14504.25	-20940.10	-57505.22
X	Profit/(loss) from discontinued operations	0.00		0.00	-	
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0	0
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0	
XIII	Profit (Loss) for the period (IX+XII)	-14948.52	-3945.16	-14504.25	-20940.10	-57505.22
XIV	Other Comprehensive Income					
	A. (i) Items that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0	0
	B. (i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
XV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	-14948.52	-3945.16	-14504.25	-20940.10	-57505.22
XVI	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000	37413000
XVII	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):					
	(a) Basic	-4.00	-1.05	-3.88	-5.60	-15.37
	(b) Diluted					

 UMANG
ALKESH
GOSALIA

 Digitally signed by
UMANG ALKESH GOSALIA
Date: 2025.05.30 19:50:12
+05'30'

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 30th May, 2025 and the same have been audited by the Statutory Auditors in compliance with Regulation 33 of SEBI (LODR) Reg., 2015. The Statutory Auditors have issued an unqualified audit report.
2. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
3. Statement of Audited Financial Results of the company for the Quarter and financial year ended 31st March, 2025, in the prescribed format under Schedule III of Companies Act, 2013
4. The figures for the previous period have been re-grouped wherever necessary.

Place: Rajkot
Date: 30.05.2025

FOR, PARMAX PHARMA LIMITED

**UMANG ALKESH
GOSALIA**

Dr. Umang Alkesh Gosalia
Managing Director

Digitally signed by UMANG
ALKESH GOSALIA
Date: 2025.05.30 19:50:41 +05'30'

Statement of Assets and Liabilities as at 31.03.2025		(in Rs. Thousands)	
Sr. No.	Particulars	As at 31.03.2025 (Audited)	As at 31.03.2024 (Audited)
I.	Assets		
1	Non-current assets		
	(a) Property, Plant and Equipment	79734.64	92716.20
	(b) Capital work-in-progress	0.00	1040.74
	(c) Investment Property	0.00	0.00
	(d) Goodwill	0.00	0.00
	(e) Other Intangible assets	0.00	0.00
	(f) Intangible assets under development	0.00	0.00
	(g) Biological Assets other than bearer plants	0.00	0.00
	(h) Financial Assets	0.00	0.00
	(i) Investments	4006.00	6.00
	(ii) Trade receivables	0.00	0.00
	(iii) Loans	1810.39	1839.34
	(i) Deferred tax assets (net)	1944.31	0.00
	(j) Other non-current assets	0.00	0.00
	Total Non-Current Assets	87495.34	95602.29
2	Current assets		
	(a) Inventories	33143.67	23949.37
	(b) Financial Assets	0.00	0.00
	(i) Investments	0	0.00
	(ii) Trade receivables	12762.57	18159.97
	(iii) Cash and cash equivalents	903.28	510.30
	(iv) Bank balances other than (iii) above	0.00	0.00
	(v) Loans	53218.90	15083.90
	(vi) Others (to be specified)	0.00	0.00
	(c) Current Tax Assets (Net)	0.00	0.00
	(d) Other current assets	0.00	0.00
	Total Current Assets	100028.42	57703.53
	Total Assets	187523.76	153305.82
II.	EQUITY AND LIABILITIES	As at 31.03.2023 (Audited)	As at 31.03.2023 (Audited)
1	Equity		
	(a) Equity Share capital	44511.50	44511.50
	(b) Other Equity	-64398.20	-43458.10
	Total Equity	-19886.70	1053.40
2	LIABILITIES		
i.	Non-current liabilities		
	(a) Financial Liabilities	0	0
	(i) Borrowings	77035.61	59064.78
	(ii) Trade payables	0	0
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	0	0
	(b) Provisions	0	0
	(c) Deferred tax liabilities (Net)		1066.65
	(d) Other non-current liabilities	0.00	0.00
	Total of Non-Current Liabilities	77035.61	60131.42
ii.	Current liabilities		
	(a) Financial Liabilities	0	0
	(i) Borrowings	0	0
	(ii) Trade payables	102153.06	73906.93
	(iii) Other financial liabilities (other than those specified in item (c))	0.00	0.00
	(b) Other current liabilities	22360.35	15960.59
	(c) Provisions	5861.44	2253.49
	(d) Current Tax Liabilities (Net)	0.00	0.00
	Total of Current Liabilities	130374.85	92121.00
	Total Equity and Liabilities	187523.76	153305.82

FOR, PARMAX PHARMA LIMITED

 UMANG ALKESH GOSALIA
Digitally signed by UMANG ALKESH GOSALIA
Date: 2025.05.30 18:49:07 +05'30'

 Dr. Umang Alkesh Gosalia
 Managing Director

 Place: Rajkot
 Date: 30.05.2025

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. **Tel.:** Fac.+91-2827-270534 - 35 - 36 **e-mail :** info@parmaxpharma.com **CIN :** L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot – 360 004, Gujarat (INDIA)

PARMAX PHARMA LIMITED

CASH FLOW STATEMENT FOR THE YEAR ENDED 31 st MARCH , 2025

(in Rs. Thousands)

PARTICULARS	Period Ended on 31/03/2025	Period Ended on 31/03/2024
(A) CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit After Extraordinary Item but Before Taxation:	-20940.10	-56558.74
Adjustments for:		
Depreciation	10316.94	17116.70
Provision for Current Tax	0.00	0.00
Current tax expenses relating to prior year	0.00	1290.50
Provision for Deferred Tax Assets	-3010.96	-344.03
Loss on account of damaged assets	10719.64	0.00
Operating profit before Working Capital changes	-2914.48	-40732.55
Adjustments for changes in Working Capital:		
(Increase) / Decrease in Inventories	-9194.30	19111.69
(Increase) / Decrease in Trade & Other Receivables	5397.40	-11932.52
(Increase) / Decrease in Short term Loans and Advances	-38135.00	6847.96
Increase / (Decrease) in Current Liabilities	34645.90	28188.51
Increase / (Decrease) in Provisions	3607.95	-7433.63
(Increase) / Decrease in Non Current Assets	0.00	3961.40
(Increase) / Decrease in Long term Loans & Advances	28.95	26.49
Cash generated from Operations	-3649.11	38769.90
Net Cash from Operating activities (A)	-6563.59	-1962.64
(B) CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	-7014.27	-15868.86
Net Cash from / (Used in) Investing activities (B)	-7014.27	-15868.86
(C) CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in other Long Term Borrowings	17970.84	14273.87
(Increase) / Decrease in Non Current Investment	-4000.00	
Net Cash (Used in) Financing activities (C)	13970.84	-14273.87
Net Increase in Cash & Cash Equivalents (A + B + C)	392.98	-3557.63
Cash & Cash Equivalents at the beginning of the year	510.28	4067.91
Cash & Cash Equivalents at the end of the year	903.26	510.28

Place: Rajkot
Date: 30.05.2025

FOR, PARMAX PHARMA LIMITED

UMANG ALKESH
GOSALIA

Digitally signed by UMANG
ALKESH GOSALIA
Date: 2025.05.30 18:54:52 +05'30'

Dr. Umang Alkesh Gosalia
Managing Director

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311,
Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Independent Auditor's Report on annual financial results of PARMAX PHARMA LIMITED pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

INDEPENDENT AUDITOR'S REPORT

TO
THE BOARD OF DIRECTORS OF
PARMAX PHARMA LIMITED

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying Statement of Financial Results of **PARMAX PHARMA LIMITED** ("the company") for the quarter and year ended **March 31, 2025**, ("the Statement"), being submitted by Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

i. Are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the **quarter ended March 31, 2025** as well as the **year to date** results for the period ended March 31, 2025



Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Electronic Address:
(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Basis of Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion subject to following Qualification:

- 1) On December 6, 2023, a fire at the Company's manufacturing facility (Plot No. 20, Survey No. 52, Hadamtala, Kotda Sangani, Rajkot, Gujarat, 360311) resulted in loss or damage to Fixed Assets, including Plant & Machinery, Factory Building, and Electrical items. The Company has recognized an amount of Rs. 3.69 Crores, described as an expenditure related to this incident, under the 'current assets' head in its standalone financial results for the quarter and year ended March 31, 2025." The Company has initiated processes with its insurers; however, as of the date of this report, a formal insurance claim has not been lodged with the insurance company, and the final amount of any recovery, including its sanction, has not yet been determined by the insurer. While the Company has provided correspondence indicating that an insurance surveyor has internally provisioned an amount of Rs. 3.5 crores related to the incident. In absence of other collaborative documents - Loss of assets and its impact on true and correctness of Profit & Loss and Balance Sheet could not be verified which has been ascertained and accounted for by the management.
- 2) Company has invested sum of Rs. 40 lakhs during the year with Aditya Birla Sun life Mutual Fund. Investment is in the name of Managing Director Umang A. Gosalia which is nominated to Namrata U. Gosalia which is in contravene of section 187 (1) of Companies Act, 2013.



Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Electronic Address:
(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists.

Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Electronic Address:
(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com



B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Electronic Address:
(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For **B A SHAH S R MEHTA & Co**

Chartered Accountants

FRN: 128796W



Malay B. Shah

Partner

M.No. 159526



Place: Rajkot

Date: 30.05.2025

UDIN : 25159526BMNYUS7145

Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Electronic Address:
(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com

- | | | |
|----|---|----------------|
| B. | Statement on Deviation or variation for proceeds of Public Issue, Right Issue, Preferential issue, Qualified institutional Placement, etc. | Not Applicable |
| C. | Format for Disclosing Outstanding default on Loans and Debt Securities. | Not Applicable |
| D. | Format for disclosure of Related Party Transactions (Applicable for only half yearly filings) | Not Applicable |
| E. | Statement on Impact of Audit Qualifications: (For Audit report with modified opinion) Submitted along with Annual Audited Financial Results (Standalone and Consolidated Separately) (Applicable only for Annual filing i.e. 4 th Quarter) | Not Applicable |

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. **Tel.:** Fac.+91-2827-270534 - 35 **Fax :** +91-2827-270536 **e-mail :** info@parmaxpharma.com **CIN :** L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)